StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Tarsus Pharmaceuticals's total debt was $72.76M at Jun 30, 2026. For fiscal 2025 it was $72.44M, up 0.8% from the year before. The highest annual figure on record is $72.44M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.44M+0.8%
FY2024Dec 31, 2024$71.85M+140.9%
FY2023Dec 31, 2023$29.82M+53.4%
FY2022Dec 31, 2022$19.43M–
FY2021Dec 31, 2021$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$72.76M+0.9%
Q1 FY2026Mar 31, 2026$72.60M+0.9%
Q4 FY2025Dec 31, 2025$72.44M+0.8%
Q3 FY2025Sep 30, 2025$72.28M+0.8%
Q2 FY2025Jun 30, 2025$72.13M+0.8%
Q1 FY2025Mar 31, 2025$71.98M+140.5%
Q4 FY2024Dec 31, 2024$71.85M+140.9%
Q3 FY2024Sep 30, 2024$71.71M+141.4%
Q2 FY2024Jun 30, 2024$71.58M+190.9%
Q1 FY2024Mar 31, 2024$29.93M+22.1%
Q4 FY2023Dec 31, 2023$29.82M+53.4%
Q3 FY2023Sep 30, 2023$29.71M+53.5%
Q2 FY2023Jun 30, 2023$24.61M+27.7%
Q1 FY2023Mar 31, 2023$24.52M+27.8%
Q4 FY2022Dec 31, 2022$19.43M–
Q3 FY2022Sep 30, 2022$19.36M–
Q2 FY2022Jun 30, 2022$19.26M–
Q1 FY2022Mar 31, 2022$19.18M–
Q4 FY2021Dec 31, 2021$0–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?